GlassScriptPhysician profile
William R Gammon
NPI 1164419941
$7,929.47
in general payments reported to CMS, 2019-2025
54 companies · $724 in 2025
The $724 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,284 · 2020: $1,005 · 2021: $1,343 · 2022: $889 · 2023: $1,449 · 2024: $1,235 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,408.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $992.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $870.92 | 2019-2024 | |
| Pfizer INC. | $655.70 | 2019-2025 | |
| Amgen INC. | $632.57 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $562.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $492.62 | 2019-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $439.50 | 2019-2022 | |
| Astellas Pharma US INC | $345.26 | 2019-2023 | Veozah |
| Janssen Pharmaceuticals, INC | $249.61 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.84 | 2020-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $179.92 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $178.81 | 2023-2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $159.39 | 2020-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $146.36 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.11 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.